Jama Oncology最新文献

{"title":"A Partnership to Advance Care of Patients With Acute Promyelocytic Leukemia.","authors":"Ross McCauley, Eunice S Wang","doi":"10.1001/jamaoncol.2024.6649","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.6649","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Toxicity of Immune Checkpoint Inhibitors-Time to Widen the Lens.","authors":"Christopher Cronin, Aoife O'Sullivan, Jarushka Naidoo","doi":"10.1001/jamaoncol.2024.6809","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.6809","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality: The ECOG-ACRIN EA9131 Trial.","authors":"Anand P Jillella, Sandra J Lee, Jessica K Altman, Selina M Luger, Martin S Tallman, James M Foran, Danielle Bradshaw, Lisa Y Law, Locke J Bryan, Abdallah Abou Zahr, Kebede H Begna, Alexander E Perl, Joseph J L Vadakara, Rubina Qamar, Raymond C Bergan, Michael J Fisch, Ruth C Carlos, Lynne I Wagner, Vamsi K Kota, Mark R Litzow","doi":"10.1001/jamaoncol.2024.7033","DOIUrl":"10.1001/jamaoncol.2024.7033","url":null,"abstract":"<p><strong>Importance: </strong>Acute promyelocytic leukemia (APL) is an acute illness that presents with cytopenia, infections, and disseminated intravascular coagulation. Achieving remission has been shown to make a major difference in patient outcomes; however, early death rates in the first month have been as high as 30% due to acute presentation, comorbidities, the rarity of APL, and clinician inexperience.</p><p><strong>Objective: </strong>To develop treatment strategies that would decrease estimated 1-month mortality from 30% to below 15%.</p><p><strong>Design, setting, and participants: </strong>In this nonrandomized clinical trial, a treatment algorithm that focused on supportive care was used to prevent early death in patients with APL treated at academic and community health centers between August 2017 and July 2021. Because of the rarity of the disease, expert support was available 24/7 from 7 designated APL experts at 6 participating academic lead centers, and included an additional 293 community centers. When a patient presented with APL, an expert was contacted and a consensus treatment plan was developed using the algorithm and expert suggestions. There were no exclusion criteria and all patients with a confirmed diagnosis of APL regardless of age or comorbid conditions were enrolled. Expert support was provided throughout induction. Initial data analysis was conducted May 2023.</p><p><strong>Main outcomes and measures: </strong>One-month mortality; additional objectives were to compare outcomes in academic and community centers and assess 1-year and overall survival.</p><p><strong>Results: </strong>A total of 201 patients were enrolled from 43 centers; 62 at lead centers and 139 from 37 community centers. The median age was 53 years (range, 18-91 years), with 72 patients (35.8%) who were aged 60 years or older; 105 patients (52.2%) were male. Fifty-two patients (26.4%) were diagnosed with high-risk APL. The 1-month mortality rate was 6 deaths of 201 patients (3.0%; 95% CI, 1.1%-6.4%) after adjusting for 1 interim analysis. In a secondary analysis using the Kaplan-Meier method, the 1-month overall survival (OS) rate was 97.0% (95% CI, 93.5%-98.6%) and the 1-year OS rate was 94.5% (95% CI, 90.3%-96.9%).</p><p><strong>Conclusions and relevance: </strong>In this nonrandomized clinical trial, use of an algorithm combined with expert support resulted in a dramatic decrease in early death in academic and community centers. Population-wide survival improved in this highly curable disease, which suggests that implementing an accessible support system with APL experts for comanagement is the most logical next step.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT03253848.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Oncology Industrial Complex-Community Oncology Must Be Given a Seat at the Table-Reply.","authors":"S Gail Eckhardt, Leonidas C Platanias","doi":"10.1001/jamaoncol.2024.7018","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.7018","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.","authors":"Gianmarco Leone, Francesco Orlando, Peter Dutey-Magni, Osvaldas Vainauskas, Emily Grist, Yari Ciani, Sharanpreet Lall, Suparna Thakali, Anna Wingate, Daniel Wetterskog, Ashwin Sachdeva, Matthew R Sydes, Neil McPhail, Thiagarajan Sreenivasan, Joe M O'Sullivan, Noel W Clarke, Mahesh K B Parmar, Louise C Brown, Nicholas D James, Francesca Demichelis, Gerhardt Attard","doi":"10.1001/jamaoncol.2024.7051","DOIUrl":"10.1001/jamaoncol.2024.7051","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Second Cancer in Erdheim-Chester Disease.","authors":"Francesco Pegoraro, Francesco Peyronel, Mohamed-Yassir Errahmani, Francesco Catamerò, Matthias Papo, Fleur Cohen-Aubart, Michelangelo Tesi, Jerome Razanamahery, Frederic Charlotte, Tanguy Le Scornet, Achille Aouba, Damien Roos-Weil, Annalisa Tondo, Elena Sieni, Zahir Amoura, Jean-François Emile, Isabella Annesi-Maisano, Augusto Vaglio, Julien Haroche","doi":"10.1001/jamaoncol.2025.0011","DOIUrl":"10.1001/jamaoncol.2025.0011","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Oncology Industrial Complex-Community Oncology Must Be Given a Seat at the Table.","authors":"Russell Gollard","doi":"10.1001/jamaoncol.2024.7015","DOIUrl":"https://doi.org/10.1001/jamaoncol.2024.7015","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polygenic Risk Scores for Prostate Cancer: Informing Prevention or Therapy.","authors":"Konrad H Stopsack","doi":"10.1001/jamaoncol.2024.5203","DOIUrl":"10.1001/jamaoncol.2024.5203","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"172-173"},"PeriodicalIF":28.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant Exercise Therapy in Patients With Prostate Cancer-Reply.","authors":"Lee W Jones, Behfar Ehdaie, Paul C Boutros","doi":"10.1001/jamaoncol.2024.5569","DOIUrl":"10.1001/jamaoncol.2024.5569","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"184-185"},"PeriodicalIF":28.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Government Funding for the Development of Enzalutamide.","authors":"Bishal Gyawali, Emily H Jung, Helen Mooney, Jerry Avorn, Aaron S Kesselheim","doi":"10.1001/jamaoncol.2024.5661","DOIUrl":"10.1001/jamaoncol.2024.5661","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"182-183"},"PeriodicalIF":28.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843347/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}